Cyclooxygenase-2 expression predicts survival in malignant pleural mesothelioma

被引：26

作者：

O'Kane, SL

Cawkwell, L

Campbell, A

Lind, MJ

机构：

[1] Univ Hull, Postgrad Med Inst, Hull York Med Sch, Kingston Upon Hull HU6 7RX, N Humberside, England

[2] Hull Royal Infirm, Kingston Upon Hull HU3 2JZ, N Humberside, England

来源：

EUROPEAN JOURNAL OF CANCER | 2005年 / 41卷 / 11期

关键词：

cyclooxygenase; immunohistochemistry; mesothelioma;

D O I：

10.1016/j.ejca.2005.04.019

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

The expression of cyclooxygenase 2 (COX-2) protein is increased in many tumours and may be associated with a more aggressive phenotype. We aimed to assess COX-2 expression in a large series of archival mesothelioma specimens. Archival tissue was obtained from 86 malignant pleural mesothelioma samples (histological subtype: 42 epithelial, 28 biphasic and 16 sarcomatoid). Overexpression of COX-2 was detected by immunohistochemical analysis. Positive staining was located in the cytoplasm of malignant tumour cells. Overall 51/86 (59%) tumour sections demonstrated COX-2 overexpression. The frequency varied with histological subtype with 31/42 (73%) of epithelial sections, 14/28 (50%) of biphasic sections and 6/16 (37%) of sarcomatoid sections recorded as positive. Kaplan Meier survival analysis indicated that overexpression of COX-2 was significantly related to improved prognosis (P < 0.001) and was an independent prognostic factor in multivariant analysis. Overexpression of COX-2 protein may confer a survival advantage in mesotheliorna patients. (c) 2005 Elsevier Ltd. All rights reserved.

引用

页码：1645 / 1648

页数：4

共 31 条

[1] Cox-2 is needed but not sufficient for apoptosis induced by Cox-2 selective inhibitors in colon cancer cells [J].

Agarwal, B ;

Swaroop, P ;

Protiva, P ;

Raj, SV ;

Shirin, H ;

Holt, PR .

APOPTOSIS, 2003, 8 (06) :649-654

[2] MALIGNANT MESOTHELIOMA - PROGNOSTIC VARIABLES IN A REGISTRY OF 180 PATIENTS, THE DANA-FARBER-CANCER-INSTITUTE AND BRIGHAM-AND-WOMENS-HOSPITAL EXPERIENCE OVER 2 DECADES, 1965-1985 [J].

ANTMAN, K ;

SHEMIN, R ;

RYAN, L ;

KLEGAR, K ;

OSTEEN, R ;

HERMAN, T ;

LEDERMAN, G ;

CORSON, J .

JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (01) :147-153

[3] Prognostic significance of cyclooxygenase-2 (COX-2) and expression of cell cycle inhibitors p21 and p27 in human pleural malignant mesothelioma [J].

Baldi, A ;

Santini, D ;

Vasaturo, F ;

Santini, M ;

Vicidomini, G ;

Di Marino, MP ;

Esposito, V ;

Groeger, AM ;

Liuzzi, G ;

Vincenzi, B ;

Tonini, G ;

Piccoli, M ;

Baldi, F ;

Scarpa, S .

THORAX, 2004, 59 (05) :428-433

[4]

Carbone M, 1999, J CELL PHYSIOL, V180, P167, DOI 10.1002/(SICI)1097-4652(199908)180:2<167::AID-JCP4>3.0.CO

[5]

2-Q

[6]

Castelao JE, 2000, BRIT J CANCER, V82, P1364

[7] Reclinical evaluation of the nonsteroidal anti-inflammatory agent celecoxib on malignant mesothelioma chemoprevention [J].

Catalano, A ;

Graciotti, L ;

Rinaldi, L ;

Raffaelli, G ;

Rodilosso, S ;

Betta, P ;

Gianni, W ;

Amoroso, S ;

Procopio, A .

INTERNATIONAL JOURNAL OF CANCER, 2004, 109 (03) :322-328

[8] Choice of management strategy for colorectal cancer based on a diagnostic immunohistochemical test for defective mismatch repair [J].

Cawkwell, L ;

Gray, S ;

Murgatroyd, H ;

Sutherland, F ;

Haine, L ;

Longfellow, M ;

O'Loughlin, S ;

Cross, D ;

Kronborg, O ;

Fenger, C ;

Mapstone, N ;

Dixon, M ;

Quirke, P .

GUT, 1999, 45 (03) :409-415

[9]

Cheng ASL, 2003, INT J ONCOL, V23, P113

[10]

Edwards JG, 2002, CLIN CANCER RES, V8, P1857

← 1 2 3 4 →